Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01PGR
|
|||
| Former ID |
DNCL002717
|
|||
| Drug Name |
SAR245409
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 2 | [1] | |
| Company |
Sanofi; Exelixis
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C13H14N6O
|
|||
| Canonical SMILES |
CCN1C2=NC(=NC(=C2C=C(C1=O)C3=CC=NN3)C)N
|
|||
| InChI |
1S/C13H14N6O/c1-3-19-11-8(7(2)16-13(14)17-11)6-9(12(19)20)10-4-5-15-18-10/h4-6H,3H2,1-2H3,(H,15,18)(H2,14,16,17)
|
|||
| InChIKey |
RGHYDLZMTYDBDT-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 934493-76-2
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
104253191, 121143586, 124757314, 125164118, 136331669, 136340221, 136348240, 136367535, 152258386, 160647223, 160962902, 162011838, 162037645, 162202600, 163783416, 163907974, 174006518, 174526238, 177749163, 185998829, 223382372, 223705077, 234218943, 242588384, 249565647, 251962690, 252110152, 252216254, 252216626, 252450473
|
|||
| ChEBI ID |
CHEBI:124914
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01936363) Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer. U.S. National Institutes of Health. | |||
| REF 2 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2156). | |||
| REF 3 | Clinical pipeline report, company report or official report of Sanofi Oncology. | |||
| REF 4 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2109). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.